10x Genomics
256 hedge funds and large institutions have $3.75B invested in 10x Genomics in 2023 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 81 increasing their positions, 100 reducing their positions, and 49 closing their positions.
358% more call options, than puts
Call options by funds: $41.1M | Put options by funds: $8.98M
3.28% less ownership
Funds ownership: 90.83% → 87.55% (-3.3%)
7% less funds holding
Funds holding: 274 → 256 (-18)
19% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 100
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
25% less capital invested
Capital invested by funds: $4.98B → $3.75B (-$1.23B)
33% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$237M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$37.4M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$24.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.5M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$18.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$67.5M |
| 2 |
SIM
SRS Investment Management
New York
|
-$58.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$36.7M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$25M |
| 5 |
GIM
Generation Investment Management
London,
United Kingdom
|
-$24.8M |
TXG Hedge Fund Activity: Q3 2023 in Review
256 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q3 2023, worth a combined $3.75B — down 25% from $4.98B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of TXG and 33 opened new positions — a net loss of 16 holders — while 100 trimmed existing stakes and 81 added.
The largest buyer was Fidelity Investments, adding an estimated $237M. The largest seller was Morgan Stanley, cutting an estimated $67.5M.
- 256 institutional investors held 10x Genomics (TXG) as of Q3 2023, down from 274 in Q2 2023.
- Funds reported $3.75B of 10x Genomics stock for Q3 2023, down 25% quarter-over-quarter.
- 33 funds opened new 10x Genomics positions in Q3 2023 and 49 closed out, a net change of -16 holders.
- The largest 10x Genomics buyer in Q3 2023 was Fidelity Investments, an estimated $237M added.
- The largest 10x Genomics seller in Q3 2023 was Morgan Stanley, an estimated $67.5M sold.
Based on aggregated 13F filings for Q3 2023.